Surface Oncology, Inc. Overview
Pro stress-test →Surface Oncology is a clinical-stage, immuno-oncology company focused on developing immunotherapies that target the tumor microenvironment. The company targets cancer patients through novel antibody candidates designed to enhance immune responses against tumors.
Strategic Profile
Pro stress-test →Surface Oncology operates two wholly-owned clinical-stage programs targeting IL-27 (SRF388) and CCR8 (SRF114), plus partnerships with Novartis targeting CD73 and GlaxoSmithKline targeting PVRIG. As a pre-revenue clinical-stage company, execution in clinical trials and regulatory progression represent the primary value drivers and execution risks.
Competitive Landscape
Pro stress-test →Surface Oncology competes in immuno-oncology against established players like Jounce Therapeutics, Calithera Biosciences, and larger pharmaceutical companies expanding into checkpoint and immunosuppression pathways. The company's earlier-stage profile and limited capitalization place it at a disadvantage against well-funded competitors with advanced pipelines and commercial infrastructure.
Industry Context
Surface Oncology, Inc. operates in Immuno-oncology therapeutics.
Key facts
Founded: 2014 · Headquarters: Cambridge, US · Employees: Unknown · Revenue: Estimated $0 (pre-commercial, clinical-stage) · Market cap: $65.08M